CN1207296C - 抑制法尼基转移酶的1,2－增环喹啉对映体 - Google Patents

抑制法尼基转移酶的1,2－增环喹啉对映体 Download PDF

Info

Publication number
CN1207296C
CN1207296C CNB018113788A CN01811378A CN1207296C CN 1207296 C CN1207296 C CN 1207296C CN B018113788 A CNB018113788 A CN B018113788A CN 01811378 A CN01811378 A CN 01811378A CN 1207296 C CN1207296 C CN 1207296C
Authority
CN
China
Prior art keywords
acid
chlorophenyl
pharmaceutically acceptable
compound
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB018113788A
Other languages
English (en)
Chinese (zh)
Other versions
CN1437601A (zh
Inventor
M·G·韦内
P·R·安日博
D·W·恩德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN1437601A publication Critical patent/CN1437601A/zh
Application granted granted Critical
Publication of CN1207296C publication Critical patent/CN1207296C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNB018113788A 2000-06-22 2001-06-13 抑制法尼基转移酶的1,2－增环喹啉对映体 Expired - Lifetime CN1207296C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00202181.4 2000-06-22
EP00202181 2000-06-22

Publications (2)

Publication Number Publication Date
CN1437601A CN1437601A (zh) 2003-08-20
CN1207296C true CN1207296C (zh) 2005-06-22

Family

ID=8171675

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018113788A Expired - Lifetime CN1207296C (zh) 2000-06-22 2001-06-13 抑制法尼基转移酶的1,2－增环喹啉对映体

Country Status (33)

Country Link
US (3) US20030114471A1 (cg-RX-API-DMAC7.html)
EP (1) EP1296984B1 (cg-RX-API-DMAC7.html)
JP (1) JP4919575B2 (cg-RX-API-DMAC7.html)
KR (2) KR100846370B1 (cg-RX-API-DMAC7.html)
CN (1) CN1207296C (cg-RX-API-DMAC7.html)
AR (1) AR030704A1 (cg-RX-API-DMAC7.html)
AT (1) ATE294804T1 (cg-RX-API-DMAC7.html)
AU (3) AU2001263962B2 (cg-RX-API-DMAC7.html)
BG (1) BG65894B1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0111743B8 (cg-RX-API-DMAC7.html)
CA (1) CA2410232C (cg-RX-API-DMAC7.html)
CZ (1) CZ295278B6 (cg-RX-API-DMAC7.html)
DE (1) DE60110592T2 (cg-RX-API-DMAC7.html)
EA (1) EA005065B1 (cg-RX-API-DMAC7.html)
EE (1) EE04966B1 (cg-RX-API-DMAC7.html)
EG (1) EG24180A (cg-RX-API-DMAC7.html)
ES (1) ES2241830T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20020989B1 (cg-RX-API-DMAC7.html)
HU (1) HU229095B1 (cg-RX-API-DMAC7.html)
IL (2) IL153560A0 (cg-RX-API-DMAC7.html)
IS (1) IS2596B (cg-RX-API-DMAC7.html)
JO (1) JO2361B1 (cg-RX-API-DMAC7.html)
MX (1) MXPA02012845A (cg-RX-API-DMAC7.html)
MY (1) MY127734A (cg-RX-API-DMAC7.html)
NO (1) NO324494B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ522481A (cg-RX-API-DMAC7.html)
PA (1) PA8519501A1 (cg-RX-API-DMAC7.html)
PL (1) PL209521B1 (cg-RX-API-DMAC7.html)
SA (1) SA01220349B1 (cg-RX-API-DMAC7.html)
SK (1) SK285699B6 (cg-RX-API-DMAC7.html)
UA (1) UA73572C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001098302A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200210305B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018135A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
AU2003229688B2 (en) 2002-04-15 2009-07-30 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
US20050003422A1 (en) 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US20180338993A1 (en) * 2014-12-04 2018-11-29 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
KR102514971B1 (ko) 2015-04-21 2023-03-27 아이거 바이오파마슈티컬스 인코포레이티드 로나파르닙 및 리토나버를 포함하는 약제 조성물
EP3277842B9 (en) 2015-08-17 2020-01-15 Kura Oncology, Inc. Methods of treating cancer patients with farnesyl transferase inhibitors
PT3534885T (pt) 2016-11-03 2021-04-13 Kura Oncology Inc Inibidores de farnesiltransferase para usar em métodos de tratamento do cancro

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1519765A (en) * 1974-09-05 1978-08-02 Ici Ltd Pesticidal dihydrotetrazolo(1,5a) quinazolines compositions and processes
US4141979A (en) * 1976-12-23 1979-02-27 Pfizer Inc. Tetrazolo[a]quinazol-5-ones antiallergy and antiulcer agents
GB9513577D0 (en) * 1995-07-04 1995-09-06 Brotherwood Rodney J Improvements in passenger carrying vehicles
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
BR9610745A (pt) * 1995-12-08 1999-07-13 Janssen Pharmaceutica Nv Derivados de (imidazol-5-il) metil-2-quinolinona inibindo a transferase da proteina farnesil
AU715658B2 (en) 1996-04-03 2000-02-10 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
WO1998049157A1 (en) * 1997-04-25 1998-11-05 Janssen Pharmaceutica N.V. Farnesyltransferase inhibiting quinazolinones
PT988038E (pt) 1997-06-02 2002-12-31 Janssen Pharmaceutica Nv Derivados (imidazol-5-il)metil-2-quinolinona como inibidores da proliferacao de celulas dos musculos lisos
JP4530537B2 (ja) * 1998-07-06 2010-08-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ インビボ放射線増感特性をもつファルネシルタンパク質トランスフェラーゼ阻害剤
HRP20000904A2 (en) 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
WO2000012499A1 (en) * 1998-08-27 2000-03-09 Pfizer Products Inc. Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
CA2341739C (en) * 1998-08-27 2005-07-12 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
KR100712226B1 (ko) * 1998-12-23 2007-04-27 얀센 파마슈티카 엔.브이. 1,2-어닐링된 퀴놀린 유도체
US6462201B1 (en) * 1998-12-29 2002-10-08 Isp Investments Inc. Process for the production of N-vinyl-2-pyrrolidone by vinylation
EE200100425A (et) * 1999-02-11 2002-12-16 Pfizer Products Inc. Heteroarüül-asendatud kinoliin-2-ooni derivaadid kui vähivastased vahendid
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
ES2293972T3 (es) 2000-02-24 2008-04-01 Janssen Pharmaceutica N.V. Regimen de dosificacion que comprende un inhibidor de la farnesil proteina transferasa para el tratamiento del cancer.
WO2002024686A2 (en) 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
AU2001293835A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives

Also Published As

Publication number Publication date
US20030114471A1 (en) 2003-06-19
EP1296984A1 (en) 2003-04-02
HUP0300872A3 (en) 2004-11-29
SK502003A3 (en) 2003-05-02
HU229095B1 (en) 2013-07-29
DE60110592D1 (de) 2005-06-09
JP2004501153A (ja) 2004-01-15
EA200300048A1 (ru) 2003-04-24
NO20026032L (no) 2002-12-16
JP4919575B2 (ja) 2012-04-18
EE04966B1 (et) 2008-02-15
MY127734A (en) 2006-12-29
IL153560A (en) 2011-06-30
HRP20020989B1 (hr) 2011-05-31
ES2241830T3 (es) 2005-11-01
US20070259902A1 (en) 2007-11-08
WO2001098302A1 (en) 2001-12-27
JO2361B1 (en) 2006-12-12
CZ2003114A3 (cs) 2003-05-14
CZ295278B6 (cs) 2005-06-15
US8318753B2 (en) 2012-11-27
PA8519501A1 (es) 2002-08-29
CN1437601A (zh) 2003-08-20
HRP20020989A2 (en) 2005-02-28
NO20026032D0 (no) 2002-12-16
KR20030009463A (ko) 2003-01-29
EA005065B1 (ru) 2004-10-28
NO324494B1 (no) 2007-10-29
UA73572C2 (en) 2005-08-15
KR100846370B1 (ko) 2008-07-15
AU2006220405B2 (en) 2009-05-21
ATE294804T1 (de) 2005-05-15
CA2410232A1 (en) 2001-12-27
NZ522481A (en) 2004-09-24
US8329714B2 (en) 2012-12-11
US20080114009A1 (en) 2008-05-15
BG65894B1 (bg) 2010-04-30
AU2006220405A1 (en) 2006-10-12
SK285699B6 (sk) 2007-06-07
SA01220349B1 (ar) 2007-01-23
HK1058363A1 (en) 2004-05-14
KR20070121847A (ko) 2007-12-27
IS6590A (is) 2002-10-25
AU6396201A (en) 2002-01-02
AU2001263962B2 (en) 2006-07-20
CA2410232C (en) 2008-10-07
BR0111743A (pt) 2003-07-08
DE60110592T2 (de) 2006-01-19
MXPA02012845A (es) 2003-05-15
PL209521B1 (pl) 2011-09-30
EG24180A (en) 2008-09-28
HUP0300872A2 (hu) 2003-07-28
ZA200210305B (en) 2004-03-19
PL358918A1 (en) 2004-08-23
BRPI0111743B1 (pt) 2019-03-26
IS2596B (is) 2010-03-15
BRPI0111743B8 (pt) 2021-05-25
KR100831940B1 (ko) 2008-05-23
EE200200695A (et) 2004-06-15
AR030704A1 (es) 2003-09-03
BG107310A (bg) 2003-07-31
IL153560A0 (en) 2003-07-06
EP1296984B1 (en) 2005-05-04

Similar Documents

Publication Publication Date Title
US8318753B2 (en) Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer
CN106795165A (zh) 咪唑并哒嗪化合物
TWI616445B (zh) 新穎環丙苯并呋喃基吡啶并吡二酮類
JP4450628B2 (ja) ファルネシルトランスフェラーゼインヒビターとして使用するためのベンジルイミダゾリル置換２−キノリンおよびキナゾリン誘導体
CN108699080A (zh) 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物
AU2001263962A1 (en) Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer
JP4537710B2 (ja) ファルネシルトランスフェラーゼ阻害剤としての炭素連結トリアゾールで置換されている１，８−アネル化キノリン誘導体
HK1058363B (en) Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer
JP4384505B2 (ja) ファルネシルトランスフェラーゼを阻害する炭素連結イミダゾールもしくはトリアゾール置換三環状キナゾリン誘導体
TWI298723B (en) Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20050622